SAT-603 Progression from Stage 1 to Stage 3 Type 1 Diabetes with Predominant Hypoglycemia

Abstract Disclosure: A.N. Nagarapu: None. J.L. Felton: None. Type 1 diabetes (T1D) is a chronic disease that progresses through well-defined stages. T1D begins in stage 1, which is defined by the presence of multiple islet autoantibodies and normal glucose tolerance. Progression to stage 2 is defined by the development of abnormal glucose tolerance, and stage 3 is defined by overt and symptomatic hyperglycemia, typically necessitating insulin initiation. Here, we present a case of a 9-year-old male with rapid progression from stage 1 to stage 3 characterized by multiple episodes of hypoglycemia. The patient presented to the emergency department (ED) when his mother was concerned that polyuria and polydipsia over the last several months suggested the development of T1D. In the ED, random glucose was 147 mg/dL (8.16 mmol/L) and HbA1c was 5.7%. Given the slightly elevated HbA1c, islet autoantibodies were ordered and he was scheduled for a follow-up outpatient oral glucose tolerance test (OGTT). However, prior to obtaining the OGTT, he returned to the ED after an episode of hypoglycemia at home (30 mg/dL (1.67 mmol/L), on home glucometer) that was treated prior to arrival in ED. Work-up at that time revealed trace ketones and repeat HbA1c of 5.4%. Islet antibody testing also revealed positive GAD and IA-2 antibodies, consistent with a diagnosis of stage 1 T1D. When he continued to have symptoms of hypoglycemia at home, he was admitted for a 24-hr controlled fast, which revealed ketotic hypoglycemia. He received nutritional counseling and was started on a continuous glucose monitor (CGM) at that time. Glucose data was reviewed one month later and demonstrated an average glucose of 112 mg/dL (6.22 mmol/L) with 94% glucoses within range (reference range 70-180 mg/dL, 3.89-9.99 mmol/L). 3 weeks later, he returned to the ED for persistent hyperglycemia (>300 mg/dL (16.65 mmol/L)), and CGM data showed a 14-day average glucose of 160 mg/dL (8.88 mmol/L) and only 45% glucoses within range. HbA1c at that time was 6.1%, consistent with stage 2 T1D, though post-prandial glucoses at home were consistent with stage 3 T1D. This case demonstrates an extremely rapid progression to symptomatic hyperglycemia that was heralded by multiple episodes of hypoglycemia. This case adds to the growing body of evidence for true hypoglycemia during early stages of T1D progression and supports further exploration of hypoglycemia in early stage T1D as a biomarker for risk for rapid progression. Presentation: Saturday, July 12, 2025

Authors

Institutions

Publication Details

Journal
Journal of the Endocrine Society
Published
2025-10-01
DOI
https://doi.org/10.1210/jendso/bvaf149.1130
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SAT-603 Progression from Stage 1 to Stage 3 Type 1 Diabetes with Predominant Hypoglycemia

Jamie L. Felton, Aakash Nagarapu
Journal of the Endocrine Society
Diabetes Management and Research
article

SAT-603 Progression from Stage 1 to Stage 3 Type 1 Diabetes with Predominant Hypoglycemia

Jamie L. Felton, Aakash Nagarapu
article en

Abstract

Abstract Disclosure: A.N. Nagarapu: None. J.L. Felton: None. Type 1 diabetes (T1D) is a chronic disease that progresses through well-defined stages. T1D begins in stage 1, which is defined by the presence of multiple islet autoantibodies and normal glucose tolerance. Progression to stage 2 is defined by the development of abnormal glucose tolerance, and stage 3 is defined by overt and symptomatic hyperglycemia, typically necessitating insulin initiation. Here, we present a case of a 9-year-old male with rapid progression from stage 1 to stage 3 characterized by multiple episodes of hypoglycemia. The patient presented to the emergency department (ED) when his mother was concerned that polyuria and polydipsia over the last several months suggested the development of T1D. In the ED, random glucose was 147 mg/dL (8.16 mmol/L) and HbA1c was 5.7%. Given the slightly elevated HbA1c, islet autoantibodies were ordered and he was scheduled for a follow-up outpatient oral glucose tolerance test (OGTT). However, prior to obtaining the OGTT, he returned to the ED after an episode of hypoglycemia at home (30 mg/dL (1.67 mmol/L), on home glucometer) that was treated prior to arrival in ED. Work-up at that time revealed trace ketones and repeat HbA1c of 5.4%. Islet antibody testing also revealed positive GAD and IA-2 antibodies, consistent with a diagnosis of stage 1 T1D. When he continued to have symptoms of hypoglycemia at home, he was admitted for a 24-hr controlled fast, which revealed ketotic hypoglycemia. He received nutritional counseling and was started on a continuous glucose monitor (CGM) at that time. Glucose data was reviewed one month later and demonstrated an average glucose of 112 mg/dL (6.22 mmol/L) with 94% glucoses within range (reference range 70-180 mg/dL, 3.89-9.99 mmol/L). 3 weeks later, he returned to the ED for persistent hyperglycemia (>300 mg/dL (16.65 mmol/L)), and CGM data showed a 14-day average glucose of 160 mg/dL (8.88 mmol/L) and only 45% glucoses within range. HbA1c at that time was 6.1%, consistent with stage 2 T1D, though post-prandial glucoses at home were consistent with stage 3 T1D. This case demonstrates an extremely rapid progression to symptomatic hyperglycemia that was heralded by multiple episodes of hypoglycemia. This case adds to the growing body of evidence for true hypoglycemia during early stages of T1D progression and supports further exploration of hypoglycemia in early stage T1D as a biomarker for risk for rapid progression. Presentation: Saturday, July 12, 2025

Journal of the Endocrine SocietyVol. 9(Supplement_1)
Indiana University School of Medicine, Saint Louis University (US), Indiana University – Purdue University Indianapolis (US)
Openalex Percentile: Top 59%
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.